Triple negative breast cancer, new therapeutic options and future strategies

Triple negative breast cancer, new therapeutic options and future strategies Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a review published on Nature Reviews – Clinical Oncology highlights the state of the art therapy in triple-negative breast cancer Triple-negative breast cancer has been viewed as the subtype with the least favorable outcomes for its […]

HER2+ and ER+ breast cancer, promising results with trastuzumab, pertuzumab and palbociclib

HER2+ and ER+ breast cancer, promising results with trastuzumab, pertuzumab and palbociclib NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as neoadjuvant therapy, with a relevant effect on Ki67 A neoadjuvant therapy with trastuzumab, pertuzumab and palbociclib reduces tumor proliferation, as shown by a drop in Ki67, in two expansion cohorts of the NA-PHER2 […]

Triple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP trial

Triple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP trial Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did not increase the rate of pathological complete remission, mostly influenced by PD-L1 expression Triple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP trial Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did […]

Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance

Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and pertuzumab, triggers sustained senescence: new data from a Michelangelo Foundation study Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and pertuzumab, triggers sustained senescence: […]